Senseonics to Present at Two Key Investor Conferences This Month
Event summary
- Senseonics will participate in Lake Street's Big Ideas Growth Conference on September 10, 2026, hosting one-on-one investor meetings.
- The company will present at H.C. Wainwright's Global Investment Conference on September 14, 2026, at 3:00 PM ET, followed by investor meetings.
- Senseonics focuses on long-term implantable continuous glucose monitoring (CGM) systems for diabetes management.
- Eversense 365 and Eversense E3 are the company's key CGM products, offering up to 365 and 180 days of glucose monitoring, respectively.
The big picture
Senseonics' participation in high-profile investor conferences underscores its push to strengthen relationships with institutional investors amid a rapidly evolving CGM market. The company's focus on long-term implantable solutions positions it uniquely, but it must demonstrate sustained commercial traction to compete with larger players. The upcoming presentations will be critical in gauging investor sentiment and potential partnerships.
What we're watching
- Market Positioning
- How Senseonics will differentiate itself in the competitive CGM market, particularly against established players like Dexcom and Abbott.
- Regulatory Dynamics
- Whether the company can navigate regulatory hurdles to expand the indications for its Eversense systems.
- Commercialization Pace
- The pace at which Senseonics can scale its commercial operations to meet growing demand for long-term CGM solutions.